Onyia Jude 4

What Happened

• Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), exercised options to acquire 11,000 shares at $84.74 per share (cost $932,140) and those 11,000 shares were sold the same day in the open market at a weighted average price of $155.53 per share (proceeds $1,710,865). The Form 4 also reports a related derivative conversion of 11,000 shares at $0 (see footnote F4 regarding the option vesting).

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (appears timely).
• Exercise: 11,000 shares acquired @ $84.74 (total $932,140).
• Sale: 11,000 shares disposed @ weighted avg $155.53 (total proceeds $1,710,865); sale prices ranged $154.47–$156.74 (F3).
• Additional derivative line: 11,000 shares reported as a conversion/disposition at $0 (derivative reporting; see F4 for vesting schedule).
• Sale execution: brokered under a Rule 10b5-1 trading plan adopted Feb 25, 2026; plan cannot be amended per issuer policy (F2).
• Footnote: filing notes 176 shares purchased Feb 27, 2026 via the company ESPP (F1).
• Shares owned after the reported transactions are not specified in the provided extract.

Context

• The exercise and same-day sale is consistent with an option exercise followed by an immediate market disposition (commonly used to cover exercise cost or realize gains). Footnote F4 explains the options’ vesting schedule; F2 confirms the sale was executed under a pre-established 10b5-1 plan. This is a routine insider sale following option exercise and should be read as a disclosure of transaction—not as explicit commentary on company prospects.